Elevated lipoprotein(a) levels predict cardiovascular disease in type 2 diabetes mellitus: a 10-year prospective cohort study
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: Elevated lipoprotein(a) (Lp[a]) level is known to be a risk factor for cardiovascular disease (CVD). However, the data that has been reported on the association between the Lp(a) level and CVD in type 2 diabetes has been limited and incoherent. The aim of this study was to investigate the relationship between the Lp(a) concentration and new onset CVD in type 2 diabetes. Methods: From March 2003 to December 2004, patients with type 2 diabetes without a prior history of CVD were consecutively enrolled. CVD was defined as the occurrence of coronary artery disease or ischemic stroke. Cox proportional hazards models were used to identify the associations between the Lp(a) and CVD after adjusting for confounding variables. Results: Of the 1,183 patients who were enrolled, 833 participants were evaluated with a median follow-up time of 11.1 years. A total of 202 participants were diagnosed with CVD (24.2%). The median Lp(a) level for 1st and 4th quartile group was 5.4 (3.5 to 7.1) and 55.7 mg/dL (43.1 to 75.3). Compared with patients without CVD, those with CVD were older, had a longer duration of diabetes and hypertension, and used more insulin and angiotensin converting enzyme inhibitors/angiotensin receptor blockers at baseline. A Cox hazard regression analysis revealed that the development of CVD was significantly associated with serum Lp(a) level (hazard ratio, 1.92; 95% confidence interval [CI], 1.26 to 2.92; p < 0.001, comparing the 4th vs. 1st quartile of Lp[a]). Conclusions: Elevated Lp(a) level was an independent predictable risk factor for CVD in type 2 diabetes. Other cardiovascular risk factors should be treated more intensively in type 2 diabetic patients with high Lp(a) levels.
Abstract
Background/Aims: Elevated lipoprotein(a) (Lp[a]) level is known to be a risk factor for cardiovascular disease (CVD). However, the data that has been reported on the association between the Lp(a) level and CVD in type 2 diabetes has been limited and incoherent. The aim of this study was to investigate the relationship between the Lp(a) concentration and new onset CVD in type 2 diabetes. Methods: From March 2003 to December 2004, patients with type 2 diabetes without a prior history of CVD were consecutively enrolled. CVD was defined as the occurrence of coronary artery disease or ischemic stroke. Cox proportional hazards models were used to identify the associations between the Lp(a) and CVD after adjusting for confounding variables. Results: Of the 1,183 patients who were enrolled, 833 participants were evaluated with a median follow-up time of 11.1 years. A total of 202 participants were diagnosed with CVD (24.2%). The median Lp(a) level for 1st and 4th quartile group was 5.4 (3.5 to 7.1) and 55.7 mg/dL (43.1 to 75.3). Compared with patients without CVD, those with CVD were older, had a longer duration of diabetes and hypertension, and used more insulin and angiotensin converting enzyme inhibitors/angiotensin receptor blockers at baseline. A Cox hazard regression analysis revealed that the development of CVD was significantly associated with serum Lp(a) level (hazard ratio, 1.92; 95% confidence interval [CI], 1.26 to 2.92; p < 0.001, comparing the 4th vs. 1st quartile of Lp[a]). Conclusions: Elevated Lp(a) level was an independent predictable risk factor for CVD in type 2 diabetes. Other cardiovascular risk factors should be treated more intensively in type 2 diabetic patients with high Lp(a) levels.
참고문헌 (39)
- Uusitupa MI, "Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects", Diabetologia, 36, pp.1175~1184 (1993)
- Almdal T, "The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up", Arch Intern Med, 164, pp.1422~1426 (2004)
- 이상열, "Prevalence of Chronic Complications in Korean Patients with Type 2 Diabetes Mellitus Based on the Korean National Diabetes Program", Diabetes and Metabolism Journal, 35(5), pp.504~512 (2011), 대한당뇨병학회
- Stevens RJ, "The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56)", Clin Sci, 101, pp.671~679 (2001)
- National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), "Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report", Circulation, 106, pp.3143~3421 (2002)
- Utermann G, "The Metabolic and Molecular Bases of Inherited Disease", pp.2753~2787 (2006), Mc-Graw-Hill, Medical Publishing Division
- Lamon-Fava S, "Lipoprotein(a)metabolism", Curr Opin Lipidol, 25, pp.189~193 (2014)
- Emerging Risk Factors Collaboration, "Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality", JAMA, 302, pp.412~423 (2009)
- Kamstrup PR, "Genetically elevated lipoprotein(a)and increased risk of myocardial infarction", JAMA, 301, pp.2331~2339 (2009)
- Danesh J, "Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies", Circulation, 102, pp.1082~1085 (2000)
- Kamstrup PR, "Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study", Lancet Diabetes Endocrinol, 1, pp.220~227 (2013)
- Qi Q, "Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes", Eur Heart J, 33, pp.325~334 (2012)
- Shai I, "A prospective study of lipoprotein(a) and risk of coronary heart disease among women with type 2 diabetes", Diabetologia, 48, pp.1469~1476 (2005)
- Hernandez C, "Lipoprotein(a) as a risk factor for cardiovascular mortality in type 2 diabetic patients: a 10-year follow-up study", Diabetes Care, 28, pp.931~933 (2005)
- Murase T, "Impact of elevated serum lipoprotein (a) concentrations on the risk of coronary heart disease in patients with type 2 diabetes mellitus", Metabolism, 57, pp.791~795 (2008)
- Hiraga T, "Prospective study of lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients with diabetes", Diabetes Care, 18, pp.241~244 (1995)
- Ginier P, "Lipoprotein(a) in patients who have non-insulin-dependent diabetes with and without coronary artery disease", Endocr Pract, 3, pp.276~280 (1997)
- 강혜미, "The Association of Self-Reported Coronary Heart Disease with Diabetes Duration in Korea", Diabetes and Metabolism Journal, 36(5), pp.350~356 (2012), 대한당뇨병학회[DOI]
- 고승현, "Higher Prevalence and Awareness, but Lower Control Rate of Hypertension in Patients with Diabetes than General Population: The Fifth Korean National Health and Nutrition Examination Survey in 2011", Diabetes and Metabolism Journal, 38(1), pp.51~57 (2014), 대한당뇨병학회[DOI]
- Levey AS, "A new equation to estimate glomerular filtration rate", Ann Intern Med, 150, pp.604~612 (2009)
- Kronenberg F, "Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: impact on lipid-lowering therapy?", Kidney Int, 66, pp.348~354 (2004)
- Kwon SW, "Prognostic significance of elevated lipoprotein(a) in coronary artery revascularization patients", Int J Cardiol, 167, pp.1990~1994 (2013)
- Nordestgaard BG, "Lipoprotein(a) as a cardiovascular risk factor: current status", Eur Heart J, 31, pp.2844~2853 (2010)
- Kostner GM, "Lipoprotein Lp(a) and the risk for myocardial infarction", Atherosclerosis, 38, pp.51~61 (1981)
- Guan W, "Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the multi-ethnic study of atherosclerosis", Arterioscler Thromb Vasc Biol, 35, pp.996~1001 (2015)
- Kamstrup PR, "Extreme lipoprotein(a) levels and improved cardiovascular risk prediction", J Am Coll Cardiol, 61, pp.1146~1156 (2013)
- Guyton JR, "Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B", Arteriosclerosis, 5, pp.265~272 (1985)
- Sandholzer C, "Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups", Hum Genet, 86, pp.607~614 (1991)
- Brown SA, "Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities: the Atherosclerosis Risk in Communities (ARIC) Study", Arterioscler Thromb, 13, pp.1139~1158 (1993)
- Jenner JL, "Effects of age, sex, and menopausal status on plasma lipoprotein(a)levels: the Framingham Offspring Study", Circulation, 87, pp.1135~1141 (1993)
- phenotypes in Caucasians and African Americans: the CARDIA study, "Arterioscler Thromb", 1993, 1037~1045
- Chien KL, "Lipoprotein (a) level in the population in Taiwan: relationship to sociodemographic and atherosclerotic risk factors", Atherosclerosis, 143, pp.267~273 (1999)
- Nielsen LB, "In vivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima", Arterioscler Thromb Vasc Biol, 17, pp.905~911 (1997)
- Baldo G, "Different apoprotein(a) isoform proportions in serum and carotid plaque", Atherosclerosis, 193, pp.177~185 (2007)
- Kamstrup PR, "Lipoprotein(a) and ischemic heart disease:a causal association? A review", Atherosclerosis, 211, pp.15~23 (2010)
- Tsimikas S, "Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes", J Am Coll Cardiol, 41, pp.360~370 (2003)
- Kronenberg F, "Epidemiology, pathophysiology and therapeutic implications of lipoprotein(a) in kidney disease", Expert Rev Cardiovasc Ther, 2, pp.729~743 (2004)
- Willeit P, "Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study", J Am Coll Cardiol, 64, pp.851~860 (2014)
- Kostner KM, "When should we measure lipoprotein (a)?", Eur Heart J, 34, pp.3268~3276 (2013)